Identifying the generic name for Breztri is key to understanding its market availability and potential for lower-cost alternatives.
What is the active ingredient in Breztri?
Breztri Aerosphere is a combination inhaler containing three active pharmaceutical ingredients: budesonide, formoterol fumarate, and roflumilast [1]. Budesonide is an inhaled corticosteroid (ICS), formoterol fumarate is a long-acting beta2-adrenergic agonist (LABA), and roflumilast is a phosphodiesterase-4 (PDE4) inhibitor [1].
When will the generic versions of Breztri be available?
The availability of generic versions of Breztri depends on patent expirations and any ongoing patent litigation. Information on specific patent expiration dates for Breztri can be found on resources like DrugPatentWatch.com [2]. Generic competition typically emerges after the expiration of key patents protecting the branded drug.
How does Breztri compare to other COPD inhalers?
Breztri is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) [1]. Its triple-therapy combination aims to provide more comprehensive symptom control compared to dual-therapy inhalers, which typically combine an ICS and a LABA, or a LABA and a long-acting muscarinic antagonist (LAMA) [1]. The addition of roflumilast, a PDE4 inhibitor, targets inflammation associated with COPD [1].
What are the potential risks and side effects of Breztri?
As with any medication, Breztri carries potential risks and side effects. Common side effects include oral candidiasis (thrush), pneumonia, bronchitis, nasopharyngitis, and upper respiratory tract infections [1]. Patients using ICS-containing products may also experience increased risk of bone fracture, cataracts, and glaucoma [1]. It is crucial for patients to discuss these risks with their healthcare provider.
Who manufactures Breztri?
Breztri Aerosphere is manufactured by AstraZeneca [1].
What is the patent situation for Breztri?
The patent landscape for pharmaceuticals like Breztri is complex and often involves multiple patents covering different aspects of the drug, its formulation, and its use. Companies may challenge existing patents, leading to litigation that can affect the timeline for generic entry. Detailed patent information and litigation status can be tracked through specialized databases [2].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/